474710-78-6

Basic information

• Product Name: Methyl 6-broMoquinazoline-4-carboxylate
• Synonyms: Methyl 6-broMoquinazoline-4-carboxylate;methyl 6-bromoquinazolin-4-carboxylate
• CAS NO: 474710-78-6
• Molecular Formula: C10H7BrN2O2
• Molecular Weight: 267.07878
• Mol File: 474710-78-6.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Methyl 6-broMoquinazoline-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 6-broMoquinazoline-4-carboxylate(474710-78-6)
• EPA Substance Registry System: Methyl 6-broMoquinazoline-4-carboxylate(474710-78-6)

Safety Data

• Hazardous Substances Data: 474710-78-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 6-bromoquinazoline-4-carboxylate is utilized as a key intermediate in the synthesis of various pharmaceutical agents. Its unique structure and properties make it an essential component in the development of new drugs and therapeutic agents.
Used in Medicinal Chemistry Research:
As a building block, Methyl 6-bromoquinazoline-4-carboxylate is employed in the synthesis of biologically active compounds for medicinal chemistry research. Its versatile chemical structure allows for the exploration of new drug candidates and the advancement of pharmaceutical science.
Used in Drug Development:
Methyl 6-bromoquinazoline-4-carboxylate is used as a precursor in the development of novel therapeutic agents. Its demonstrated biological activity and potential applications in various studies make it a promising candidate for the creation of innovative treatments and interventions.

Upstream product

• 67-56-1 methanol 
• 474710-80-0 ammonium 6-bromoquinazoline-4-carboxylate 
• 551-93-9 2-aminoacetophenone 
• 29124-56-9 1-(2-amino-5-bromophenyl)ethanone 
• 69674-27-7 6-bromo-4-methylquinazoline 
• 769916-07-6 C₉H₅BrN₂O₂ 

Relevant articles and documents

SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT

This disclosure relates to low molecular weight substituted imidazoles that inhibit the TGF-b signaling pathway. More specifically, this disclosure relates to methods of using said imidazoles for the treatment of diseases related to the TGF-b signaling pathways including, but not limited to, atherosclerosis, Marfan syndrome, Loeys-Dietz syndrome, obesity, diabetes, multiple sclerosis, keratoconus, idiopathic pulmonary fibrosis, Alzheimer's Disease, chronic kidney disease, and scleroderma.

NITROGENOUS FUSED?RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF

The present invention provides a compound having an excellent inhibitory action on activation of STAT6 and a pharmaceutical composition thereof. Inparticular, it provides a compound represented by the following formula (I), a salt thereof or a hydrate of them. In the formula, X represents a nitrogen-containing condensed aromatic heterocyclic group such as imidazo[1,2-a]pyridine, benzimidazole, quinazoline, quinoline, or 2,1-benzisoxazole and has (R4)n as substituent groups; Y represents a C3-8 cycloalkyl group, C4-8 cycloalkenyl group, 5- to 14-membered non-aromatic heterocyclic group, C6-14 aromatic hydrocarbon cyclic group or 5- to 14-membered aromatic heterocyclic group; n in (R4)n is 0, 1, 2 or 3, and Z groups independently represent (1) hydrogen atom, (2) amino group, (3) halogen atom, (4) hydroxyl group, (5) nitro group, (6) cyano group, (7) azido group, (8) formyl group, (9) hydroxyamino group, (10) sulfamoyl group, (11) guanodino group, (12) oxo group, (13) C2-6 alkenyl group, (14) C1-6 alkoxy group, (15) C1-6 alkylhydroxyamino group, (16) halogenated C1-6 alkyl group, (17) halogenated C2-6 alkenyl group, (18) (i) C3-7cycloalkyl group, (ii) C3-7cycloalkenyl group, (iii) 5- to 14-membered non-aromatic heterocyclic group, each of which may have one or more substituent groups Q, or (19) formula -M1-M2-M3, R1 represents (1) hydrogen atom, (2) halogen atom, (3) hydroxyl group, (4) nitro group, (5) cyano group, (6) halogenated C1-6 alkyl group, (7) C2-6 alkyl group substituted with a hydroxyl or cyano group, (8) C2-6 alkenyl group, or (9) formula -L1-L2-L3, and R2 represents a hydrogen atom or a protecting group; and R3 represents a hydrogen atom, halogen atom, cyano group, amino group, C1-4 alkyl group or halogenated C1-4 alkyl group.